Alkermes Rides Into 2014 On Abilify’s Coattails
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on its experience in long-acting injectables, Alkermes is preparing to file an NDA for its long-acting version of Otsuka/Bristol-Myers Squibb’s antipsychotic Abilify in 2014.